Pure Monograph

Pure Monograph vs Certara CoAuthor

Both products apply AI to regulatory writing, but they approach the problem from different angles. CoAuthor embeds inside Microsoft Word for medical writers. Pure Monograph is a web-first authoring and intelligence platform that covers CMC, tech transfer, and pipeline intelligence in addition to medical-writing-adjacent drafting.

Short answer. CoAuthor is an enterprise-focused, Word-plugin, human-in-the-loop writing assistant rebranded from Synchrogenix Writer in June 2024. Pure Monograph is a web platform covering Module 3 CMC, tech transfer, BMR, stability, and intelligence. Different form factor, different scope, partial overlap at the CTD narrative layer.

At a glance

DimensionPure MonographCertara CoAuthor
Primary deliverableCTD Module 3, tech transfer packages, BMRs, stability, intelligence briefsRegulatory writing deliverables drafted and reviewed inside Word
CategoryWeb SaaS + concierge packagesEnterprise AI plugin for MS Word
Regulatory outputModule 3, ICH Q-series, 21 CFR, USP aligned drafts exported as Word/PDF/ExcelClinical and regulatory documents with human-in-the-loop reference checking
WorkflowBrowser, no install; direct Word/PDF/Excel exportMicrosoft Word plugin, integrates with Word track-changes and referencing
Pricing$0-$1,499 per month self-serve; $7,500-$80,000 USD request-basedEnterprise licensing (Certara Nasdaq: CERT)
Engagement modelSelf-serve plus optional conciergeEnterprise sales + services partnership
OwnershipBurrard Pharmaceutical Enterprises Ltd., Vancouver BCCertara (Nasdaq: CERT). CoAuthor rebranded from Synchrogenix Writer June 2024.

Where CoAuthor wins

CoAuthor is built for enterprise medical writing teams that live in Word. Its human-in-the-loop model, reference management, and integration with Certara's broader Regulatory Writing practice are hard to beat for high-volume CSR and Module 2 authoring at large pharma.

Where Pure Monograph wins

Pure Monograph is stronger outside pure medical writing: Module 3 CMC sections, ICH Q1-based stability protocols, ICH Q9(R1) FMEA risk registers, 21 CFR 211.188 BMRs, ICH Q5E comparability content, and pharmaceutical intelligence (pipeline, patent, news). The self-serve pricing also removes the enterprise-contract floor that CoAuthor sits behind.

Using both in sequence

A pragmatic pattern: draft Module 3 CMC in Pure Monograph, export to Word, hand off to the regulatory medical writing team using CoAuthor for final reference checking and style enforcement. The Module 2 clinical summary work stays in CoAuthor end-to-end.

Frequently asked questions

What is Certara CoAuthor?

CoAuthor is Certara's AI-assisted regulatory writing product. It was rebranded from Synchrogenix Writer in June 2024 and runs as a human-in-the-loop plugin inside Microsoft Word, targeting regulatory medical writers at enterprise sponsors.

How is Pure Monograph different?

Pure Monograph is a web-first AI platform covering CTD Module 3, tech transfer, BMRs, stability, and intelligence. It does not install inside Word; it exports Word, PDF, and Excel. It also covers intelligence surfaces CoAuthor does not.

Which fits enterprise regulatory medical writing teams?

Teams built around Word-centric workflows and high-volume medical writing typically adopt CoAuthor. Teams that need Module 3 CMC, tech transfer, and broader intelligence coverage lean toward Pure Monograph.

Can both be used together?

Yes. Draft CMC in Pure Monograph, export to Word, continue in CoAuthor with reference checking and style enforcement.